Lupin Share Price Today (LUPIN)
TODAY IN ONE LINE
LUPIN slipped 0.6% on average volume, in line with Nifty's -0.0% move, supported by recent strong earnings.
With a market cap of ₹1.09 L Cr., it trades at a P/E of 20.56. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Lupin flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 89.0% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 31.9% and Profit up 101.0%
- ●High Capital EfficiencyROCE of 30.3% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 29.1%
- ●Healthy Operating MarginsOPM is structurally strong at 31.5%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Lupin News
What changed recently?
Recent events, corporate actions, and announcements.
Lupin Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Lupin Limited, framed against the sector median so the premium or discount is obvious at a glance.
Lupin Limited trades at a P/E of 20.56× and P/B of 4.88×, against the Healthcare sector median P/E of 40.97×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Lupin Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Lupin Limited — derived from the live tape, not yesterday's close.
Lupin Limited last traded at ₹2,395.8 with an intraday range of ₹2,383.3–₹2,416.8 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹2395.80| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2480.97 | +85.17 | +3.55% |
| R3 | 2447.47 | +51.67 | +2.16% |
| R2 | 2432.13 | +36.33 | +1.52% |
| R1 | 2413.97 | +18.17 | +0.76% |
| PIVOT | 2398.63 | 2.83 | 0.12% |
| CURRENT | 2395.80 | — | — |
| S1 | 2380.47 | -15.33 | -0.64% |
| S2 | 2365.13 | -30.67 | -1.28% |
| S3 | 2346.97 | -48.83 | -2.04% |
| S4 | 2313.47 | -82.33 | -3.44% |
LUPIN is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹2401.2–₹2416.8
Trading Inside opening range
Lupin Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Lupin Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Lupin Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1.09 L Cr. and reported EPS of ₹116.56.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 22,708 | 27,958 ▲ 23.1% |
| Sales Growth YoY %Derived | 13.48% | 23.12% |
| Other Income | 196 | 424 ▲ 116.8% |
| Total Income | 22,904 | 28,382 ▲ 23.9% |
| 6,842 | 7,326 ▲ 7.1% | |
| Gross ProfitDerived | 15,866 | 20,632 ▲ 30.0% |
| Gross Margin %Derived | 69.87% | 73.79% |
| 10,582 | 11,816 ▲ 11.7% | |
| EBITDA (Operating Profit)Derived | 5,283 | 8,816 ▲ 66.9% |
| OPM %Derived | 23.27% | 31.53% |
| 1,464 | 1,252 ▼ 14.5% | |
| Profit Before Tax (PBT) | 4,015 | 6,873 ▲ 71.2% |
| 709 | 1,517 ▲ 114.1% | |
| Effective Tax %Derived | 17.65% | 22.07% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 3,306 | 5,355 ▲ 62.0% |
| Less: Non-controlling Interests | 25 | 23 ▼ 8.2% |
| Net Profit (Owner's PAT)Derived | 3,282 | 5,333 ▲ 62.5% |
| Net Profit Margin %Derived | 14.45% | 19.07% |
| PAT Growth YoY %Derived | 71.41% | 62.51% |
| Earnings Per Share (EPS ₹) | 71.88 | 116.65 ▲ 62.3% |
| Diluted Shares Outstanding (Cr) | 46 | 46 ▲ 0.1% |
| Share of Profit from Associates/JVs | — | — |
| Other Comprehensive Income (Net of Tax) | -91 | 440 ▲ 581.5% |
| Total Expenses (incl. D&A & Interest) | 18,889 | 21,510 ▲ 13.9% |
| Material Cost % of RevenueDerived | 19.63% | 16.53% |
| Employee Cost % of RevenueDerived | 17.46% | 16.36% |
| Other Cost % of RevenueDerived | 29.14% | 25.90% |
| Interest Coverage (x)Derived | 13.95x | 17.12x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 15,560 | 16,369 ▲ 5.2% | 15,375 ▼ 6.1% | 15,163 ▼ 1.4% | 16,405 ▲ 8.2% | 16,642 ▲ 1.4% | 20,011 ▲ 20.2% | 22,708 ▲ 13.5% | 27,958 ▲ 23.1% | |
| Sales Growth YoY %Derived | — | 5.20% | -6.08% | -1.38% | 8.19% | 1.44% | 20.25% | 13.48% | 23.12% | |
| Other Income | 395 | 713 ▲ 80.6% | 484 ▼ 32.1% | 136 ▼ 71.8% | 142 ▲ 4.0% | 73 ▼ 48.2% | 120 ▲ 63.8% | 196 ▲ 63.0% | 424 ▲ 116.8% | |
| Total Income | 15,955 | 17,082 ▲ 7.1% | 15,859 ▼ 7.2% | 15,299 ▼ 3.5% | 16,547 ▲ 8.2% | 16,715 ▲ 1.0% | 20,131 ▲ 20.4% | 22,904 ▲ 13.8% | 28,382 ▲ 23.9% | |
5,274 | 5,846 ▲ 10.8% | 5,431 ▼ 7.1% | 5,362 ▼ 1.3% | 6,481 ▲ 20.9% | 6,780 ▲ 4.6% | 6,643 ▼ 2.0% | 6,842 ▲ 3.0% | 7,326 ▲ 7.1% | ||
| Gross ProfitDerived | 10,285 | 10,524 ▲ 2.3% | 9,944 ▼ 5.5% | 9,801 ▼ 1.4% | 9,924 ▲ 1.3% | 9,862 ▼ 0.6% | 13,367 ▲ 35.5% | 15,866 ▲ 18.7% | 20,632 ▲ 30.0% | |
| Gross Margin %Derived | 66.10% | 64.29% | 64.68% | 64.64% | 60.49% | 59.26% | 66.80% | 69.87% | 73.79% | |
7,382 | 7,990 ▲ 8.2% | 7,589 ▼ 5.0% | 7,234 ▼ 4.7% | 9,637 ▲ 33.2% | 8,064 ▼ 16.3% | 9,557 ▲ 18.5% | 10,582 ▲ 10.7% | 11,816 ▲ 11.7% | ||
| EBITDA (Operating Profit)Derived | 2,903 | 2,533 ▼ 12.7% | 2,355 ▼ 7.1% | 2,567 ▲ 9.0% | 287 ▼ 88.8% | 1,798 ▲ 526.0% | 3,811 ▲ 111.9% | 5,283 ▲ 38.7% | 8,816 ▲ 66.9% | |
| OPM %Derived | 18.66% | 15.48% | 15.32% | 16.93% | 1.75% | 10.80% | 19.04% | 23.27% | 31.53% | |
-174 | 1,057 ▲ 706.8% | 581 ▼ 45.0% | 1,028 ▲ 76.9% | 1,801 ▲ 75.2% | 1,155 ▼ 35.9% | 1,508 ▲ 30.6% | 1,464 ▼ 2.9% | 1,252 ▼ 14.5% | ||
| Profit Before Tax (PBT) | 543 | 1,517 ▲ 179.3% | 753 ▼ 50.3% | 1,675 ▲ 122.4% | -1,373 ▼ 181.9% | 716 ▲ 152.2% | 2,422 ▲ 238.1% | 4,015 ▲ 65.8% | 6,873 ▲ 71.2% | |
288 | 902 ▲ 212.6% | 1,157 ▲ 28.3% | 449 ▼ 61.2% | 137 ▼ 69.4% | 269 ▲ 96.0% | 487 ▲ 81.1% | 709 ▲ 45.6% | 1,517 ▲ 114.1% | ||
| Effective Tax %Derived | 53.10% | 59.43% | 153.61% | 26.78% | -9.99% | 37.52% | 20.09% | 17.65% | 22.07% | |
| Profit/Loss from Discontinued Ops | — | — | 130 | — ▼ 100.0% | — | — | — | — | — | |
| Total Profit for Period | 258 | 615 ▲ 138.2% | -270 ▼ 143.8% | 1,228 ▲ 555.2% | -1,509 ▼ 222.9% | 448 ▲ 129.7% | 1,936 ▲ 332.3% | 3,306 ▲ 70.8% | 5,355 ▲ 62.0% | |
| Less: Non-controlling Interests | 7 | 9 ▲ 26.0% | 3 ▼ 69.8% | 11 ▲ 322.2% | 19 ▲ 63.9% | 18 ▼ 5.7% | 21 ▲ 19.8% | 25 ▲ 16.8% | 23 ▼ 8.2% | |
| Net Profit (Owner's PAT)Derived | 251 | 607 ▲ 141.4% | -272 ▼ 144.9% | 1,217 ▲ 546.5% | -1,528 ▼ 225.6% | 430 ▲ 128.1% | 1,914 ▲ 345.1% | 3,282 ▲ 71.4% | 5,333 ▲ 62.5% | |
| Net Profit Margin %Derived | 1.61% | 3.71% | -1.77% | 8.02% | -9.31% | 2.58% | 9.57% | 14.45% | 19.07% | |
| PAT Growth YoY %Derived | — | 141.40% | -144.92% | 546.47% | -225.61% | 128.15% | 345.15% | 71.41% | 62.51% | |
| Earnings Per Share (EPS ₹) | 5.56 | 13.40 ▲ 141.0% | -6.02 ▼ 144.9% | 26.81 ▲ 545.3% | -33.62 ▼ 225.4% | 9.45 ▲ 128.1% | 42.01 ▲ 344.6% | 71.88 ▲ 71.1% | 116.65 ▲ 62.3% | |
| Diluted Shares Outstanding (Cr) | 45 | 45 ▲ 0.1% | 45 ▲ 0.1% | 45 ▲ 0.2% | 45 ▲ 0.2% | 45 ▲ 0.1% | 46 ▲ 0.2% | 46 ▲ 0.2% | 46 ▲ 0.1% | |
| Share of Profit from Associates/JVs | 4 | — ▼ 100.0% | 4 | 1 ▼ 66.2% | 0 ▼ 72.9% | — ▼ 100.0% | — | — | — | |
| Other Comprehensive Income (Net of Tax) | 138 | -234 ▼ 269.4% | -608 ▼ 160.1% | 262 ▲ 143.1% | 104 ▼ 60.3% | 24 ▼ 76.7% | 38 ▲ 55.2% | -91 ▼ 343.3% | 440 ▲ 581.5% | |
| Total Expenses (incl. D&A & Interest) | 15,411 | 15,565 ▲ 1.0% | 15,105 ▼ 3.0% | 13,624 ▼ 9.8% | 17,920 ▲ 31.5% | 15,999 ▼ 10.7% | 17,709 ▲ 10.7% | 18,889 ▲ 6.7% | 21,510 ▲ 13.9% | |
| Material Cost % of RevenueDerived | 18.99% | 21.75% | 20.58% | 20.90% | 19.72% | 22.16% | 20.70% | 19.63% | 16.53% | |
| Employee Cost % of RevenueDerived | 18.41% | 19.25% | 19.43% | 18.64% | 18.22% | 18.55% | 17.46% | 17.46% | 16.36% | |
| Other Cost % of RevenueDerived | 29.03% | 29.56% | 29.94% | 29.07% | 40.52% | 29.90% | 30.29% | 29.14% | 25.90% | |
| Interest Coverage (x)Derived | 8.89x | 4.71x | 3.81x | 11.94x | -9.61x | 3.34x | 8.39x | 13.95x | 17.12x |
Lupin segment analysis : revenue and profit mix.
Disclosed business segments at Lupin with their share of revenue and profit, switchable between consolidated and standalone reporting.
Lupin discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Lupin Limited.
Our AI distills the core fundamental drivers supporting Lupin Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Lupin Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 89% YoY, demonstrating robust earnings acceleration and operational excellence.
ROE 29.10% and ROCE 30.30% substantially exceed pharmaceutical sector averages, indicating superior capital efficiency.
Operating margin 53.41% reflects exceptional pricing power and operational efficiency versus industry peers.
Market cap ₹1.10 LCr with minimal debt ₹0.07 LCr provides financial stability and strategic flexibility.
Promoter holding 46.85% ensures strong management alignment with long-term shareholder value creation.
Key Risks.
Operating cash flow declined from ₹5,539.85 Cr to ₹2,504.91 Cr, signaling deteriorating cash generation quality.
Dividend yield 0.48% is substantially low, limiting income returns for equity investors seeking dividends.
Public shareholding only 6.06% amplifies stock price volatility from institutional trading activity.
Free cash flow turned negative at ₹-109 Cr in H1 FY2026, raising concerns about capital allocation sustainability.
Heavy capex of ₹5,738 Cr in H1 FY2026 constrains free cash flow despite positive operating cash flow.
Flip Conditions.
Valuation risk. a P/E above 27 (~0.7× the sector multiple of 41.0) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 24% would indicate weaker capital compounding.
Lupin Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Lupin Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Lupin Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Lupin Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Lupin Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Lupin Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Lupin Limited stood at 63.7% of traded volume, against a 20-day average of 57.9%.
Lupin announcements: results, concalls, ratings, M&A.
Filings Lupin sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Lupin files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 281 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Lupin Limited has informed the Exchange about Schedule of Earnings Call for Q1 FY27.
Acquisition
Lupin Limited has informed the Exchange about Lupin Inc. U.S.A., wholly owned subsidiary of the Company has entered into a licensing agreement in…
Copy of Newspaper Publication
Lupin Limited has informed the Exchange about copy of Newspaper Publication relating to Annual General Meeting and e-voting related information.
Press Release
Lupin Limited has informed the Exchange regarding a press release dated July 14, 2026, titled "Lupin Recognized Among India s Best Employers in the…
Updates
Lupin Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report of the Company for FY 2025-26'.
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Press Release
Investor Presentation
Lupin dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Lupin has declared, sequenced by announce and record date.
Lupin corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Lupin Limited: business, sector, key facts.
What Lupin Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Lupin Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: LUPIN, BSE: 500257.
Lupin Limited is a multinational pharmaceutical company headquartered in Mumbai, India, with a global presence. Established in 1968 (formerly Lupin Chemicals Limited), the company's core business involves the entire pharmaceutical value chain, from drug discovery and development to manufacturing, marketing, and sales.
Lupin's product portfolio is extensive and diverse, encompassing branded and generic formulations, biosimilars, over-the-counter medications, and specialty drugs. A significant portion of their business centers around the production and supply of Active Pharmaceutical Ingredients (APIs), the fundamental building blocks of many pharmaceutical products. This vertical integration allows for greater control over quality and cost.
The company caters to a wide range of therapeutic areas, reflecting a commitment to addressing diverse health needs. These areas include, but are not limited to, anti-tuberculosis treatments, diabetes management, cardiovascular health, respiratory diseases (COPD and asthma), women's health, central nervous system disorders, oncology, immunology, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal health, anti-infective therapies, and nonsteroidal anti-inflammatory drugs. This broad therapeutic focus positions Lupin as a significant player in the global pharmaceutical market.
Beyond its core manufacturing and distribution activities, Lupin is also engaged in bio-clinical research. This commitment to research and development underpins their ability to innovate and bring new and improved treatments to market. Furthermore, the company's operational network includes laboratories, collection centers (LupiMitra), and pickup points, suggesting a robust infrastructure designed to support its extensive operations and reach a wide patient base.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Lupin Limited (LUPIN).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Lupin Limited (LUPIN)?
The current share price of Lupin Limited (LUPIN) is ₹2,395.8. Today, the stock has declined by ₹14.20 (0.59%), trading in a range of ₹2,383.3 to ₹2,416.8. The stock opened at ₹2,409.2 with a trading volume of 6,07,756 shares.
02Is Lupin Limited stock a good investment for long-term?
Lupin Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,09,356.3 crores, P/E ratio of 20.56, ROE of 29.10%, and ROCE of 30.30%. The dividend yield stands at 0.48%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Lupin Limited stock?
The 52-week high price of Lupin Limited (LUPIN) is ₹2,529.5, while the 52-week low is ₹1,836.8. Currently trading at ₹2,395.8, the stock is 80.7% away from its 52-week low and 5.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Lupin Limited stock at the current price?
Whether to buy Lupin Limited stock at ₹2,395.8 depends on multiple factors. The stock is currently trading with a P/E ratio of 20.56 and P/B ratio of 4.88. Today's performance shows a loss of 0.59%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Lupin Limited and when is the next dividend?
Lupin Limited offers a dividend yield of 0.48%, which means for every ₹100 invested at the current price of ₹2,395.8, you can expect to receive approximately ₹0.48 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Lupin Limited?
Lupin Limited's key financial metrics include: P/E Ratio: 20.56, P/B Ratio: 4.88, ROE: 29.10%, ROCE: 30.30%, Dividend Yield: 0.48%, EPS: ₹116.56, Book Value: ₹491.29, and Debt-to-Equity: 0.29. The company's market cap stands at ₹1,09,356.3 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Lupin Limited stock performing today in the market?
Lupin Limited stock opened at ₹2,409.2 and is currently trading at ₹2,395.8, showing a decline of ₹14.20 (0.59%). The intraday high is ₹2,416.8 and low is ₹2,383.3. The trading volume stands at 6,07,756 shares, indicating moderate market participation today.
08What is the P/E ratio of Lupin Limited and what does it indicate?
Lupin Limited has a Price-to-Earnings (P/E) ratio of 20.56, which means investors are willing to pay ₹20.56 for every ₹1 of earnings. With an EPS of ₹116.56, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Lupin Limited (LUPIN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.